Details of the Drug Combination

General Information of Drug Combination (ID: DCF5VPL)

Drug Combination Name

Indazole derivative 5 Vinflunine

Indication

Disease Entry	Status	REF
Glioma	Investigative	[1]

Component Drugs

Indazole derivative 5 DMM1I8R

Vinflunine DMTJAEP

Small molecular drug

2D MOL

3D MOL

High-throughput Screening Result

Testing Cell Line: SF-539

Zero Interaction Potency (ZIP) Score: 1.87

Bliss Independence Score: 2.44

Loewe Additivity Score: 5.23

LHighest Single Agent (HSA) Score: 6.24

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)

Indazole derivative 5 Interacts with 2 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
ABL T315I mutant (ABL T315I)	TTZJTWA	ABL1_HUMAN	Inhibitor	[3]
Fusion protein Bcr-Abl T315I mutant (Bcr-Abl T315I)	TTIV39N	BCR_HUMAN-ABL1_HUMAN	Inhibitor	[3]
------------------------------------------------------------------------------------

Indication(s) of Vinflunine

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Approved	[2]

Test Results of This Drug Combination in Other Disease Systems

Indication	DrugCom ID	Cell Line	Status	REF
Adult T acute lymphoblastic leukemia	DCM44Q2	MOLT-4	Investigative	[1]
Amelanotic melanoma	DCDRWS3	MDA-MB-435	Investigative	[4]
------------------------------------------------------------------------------------

References

1	Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
2	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
3	Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412.
4	Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.